Press release from Business Wire
Ryan & Maniskas, LLP Announces Investigation of Ceradyne Inc.
Tuesday, October 02, 2012
Ryan & Maniskas, LLP Announces Investigation of Ceradyne Inc.10:43 EDT Tuesday, October 02, 2012 WAYNE, Pa. (Business Wire) -- Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/crdn) is investigating potential claims against the board of directors of Ceradyne Inc. (“Ceradyne” or the “Company”) (NASDAQ: CRDN) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to 3M Co. in an all-cash deal valued at approximately $860 million. Our investigation concerns possible breaches of fiduciary duty and other violations of law related to the approval of the transaction by the Company's board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for all shareholders of Ceradyne. For more information regarding our investigation, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at email@example.com or visit: www.rmclasslaw.com/cases/crdn Under the terms of the proposed transaction, Ceradyne's stockholders will receive $35 in cash for each share of Ceradyne's common stock they own. If you own shares of Ceradyne and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/crdn. You may also email Mr. Maniskas at firstname.lastname@example.org. For more information about class action cases in general, please visit our website: www.rmclasslaw.com. Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide. Ryan & Maniskas, LLPRichard A. Maniskas, Esquire877email@example.com/cases/crdn